IDB Holland bv is a Health Canada authorized supplier of Lutetium-177 (Lu-177). Lu-177 is a nuclear medicine treatment used to improve the quality of life in patients with neuroendocrine cancer.
Lawson collaborated with IDB Holland bv in a clinical trial called “An Open Label Phase II, Registry Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Subjects with Somatostatin Receptor Positive Tumours.” The trial was undertaken to test the efficacy of Lu-177 treatment. Prior to this trial, patients were required to travel to either Europe or Edmonton for this specialized, targeted therapy.
“IDB Holland has worked with us to collaborate on our Health Canada approved trial to enable patient access to this treatment in Ontario,” says Dr. Jonathan Romsa, Chief in Nuclear Medicine at London Health Sciences Centre and St. Joseph’s Health Care London, and Chair, Division of Nuclear Medicine at Western University’s Schulich School of Medicine & Dentistry.
IDB Holland went above and beyond in delivering quality shipments in a timely manner, requiring complicated dangerous goods handling across multiple borders from Holland to Canada. IDB Holland also ensured significant cost savings during product price increases.
“The cooperation between Lawson and IDB Holland is excellent. Our relationship is based on trust, transparency and flexibility,” says Philippe van Overeem, Managing Director for IDB Holland bv.
This collaboration, and the exceptional support from IDB Holland, helped to provide an Ontario-based treatment program for patients, eliminating the requirement to travel to Europe or Edmonton for specialized, targeted therapy.
Learn more about IDB Holland’s Industry Partner of the Year Award:
The Industry Partner of the Year Award was established in 1997 to recognize industry that understands and supports research. The award is given to private sector partners that help Lawson move closer to its goal of improving the quality of health care in Canada and around the world.
